Mr. Gentaro Tajima received his Ph.D. from Gifu Pharmaceutical University, Gifu, Japan, in 2022. He started his career as a toxicologist in the safety laboratory of Wyeth Lederle Japan, then moved to the Wyeth clinical operations department, and then to the project management department of Pfizer Japan. He is currently a Japan Regulatory Lead, and has specialized in the gene therapy field for more than 6 years at the department of regulatory affairs, Pfizer R&D Japan G.K. in Tokyo, Japan.
Outside of the company, he is a member of PhRMA Japan and facilitates a discussion group of five pharmaceutical trade associations to promote process improvement of the Cartagena Act in Japan. He is also the contact person for the Japanese regulatory authorities PMDA, MHLW, and AMED's research group as an academic on Cartagena Act process improvement.